R&G PharmaStudies (301333)2025-04-27 07:41Financial Performance - The company's revenue for Q1 2025 was ¥172,843,520.58, a decrease of 2.53% compared to ¥177,331,193.71 in the same period last year[5] - Net profit attributable to shareholders increased by 13.12% to ¥26,073,749.86 from ¥23,048,890.81 year-on-year[5] - Basic and diluted earnings per share rose by 12.50% to ¥0.27 from ¥0.24 in the same period last year[5] - Net profit for the current period is ¥26,410,752.58, an increase of 11.8% compared to ¥23,572,914.21 in the previous period[37] - Earnings per share (basic and diluted) increased to ¥0.27 from ¥0.24, reflecting a growth of 12.5%[38] Cash Flow - The net cash flow from operating activities was negative at -¥11,193,588.94, a decline of 148.04% compared to ¥23,298,356.28 in the previous year[5] - Cash flow from operating activities decreased to ¥149,075,749.65, down 13.0% from ¥171,279,223.23 in the previous period[40] - Net cash flow from operating activities was -23.30 million in the previous period[41] - Net cash flow from financing activities showed a dramatic increase of 390.80%, amounting to -¥45,417,320.31 compared to -¥9,253,748.32 in the previous year[12] - Net cash flow from financing activities was -9.25 million in the previous year[41] Assets and Liabilities - Total assets decreased by 2.22% to ¥2,284,458,257.48 from ¥2,336,225,321.98 at the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 757,135,831.99 from CNY 1,068,707,741.15, reflecting a decline of approximately 29.1%[33] - Total liabilities decreased to ¥417,164,475.26 from ¥500,089,008.78, a reduction of 16.6%[35] - Total equity increased to ¥1,867,293,782.22 from ¥1,836,136,313.20, reflecting a growth of 1.7%[35] Investments and Subsidiaries - The company established a wholly-owned subsidiary, R&G (HK) PHARMA LIMITED, in Hong Kong on February 14, 2025[30] - The company also established another wholly-owned subsidiary, R&G PHARMA AUSTRALIA PTY LIMITED, in Australia on February 19, 2025[31] - Total cash inflow from investment activities was 650.67 million year-over-year[41] - Cash outflow from investment activities totaled 845.27 million in the prior period[41] Shareholder Actions - The total number of ordinary shareholders at the end of the reporting period was 7,041[13] - The company plans to repurchase shares using its own funds, with a total amount not less than RMB 50 million and not exceeding RMB 80 million, at a price not exceeding RMB 58.00 per share[17] - As of March 31, 2025, the company has repurchased a total of 1,442,000 shares, accounting for 1.49% of the total share capital, with a total transaction amount of RMB 56,062,734.00[18] - Harmony Growth Phase II and its concerted actors plan to reduce their holdings through block trading and centralized bidding on November 14, 2024[20] - From February 26 to March 5, 2025, Harmony Growth Phase II and Harmony Health cumulatively reduced their holdings by 2,126,238 shares, accounting for 2.2240% of the company's total share capital[21] Research and Development - Research and development expenses for the current period were ¥14,474,466.24, slightly up from ¥14,126,228.84, indicating a focus on innovation[37] Other Financial Metrics - The company reported a significant increase of 34.30% in trading financial assets, reaching ¥950,333,744.66 due to an increase in bank cash management products[10] - The company's accounts receivable rose to CNY 145,756,042.92 from CNY 125,239,485.50, indicating an increase of approximately 16.5%[33] - The company's contract liabilities decreased to CNY 220,807,328.88 from CNY 235,117,501.62, a decline of approximately 6.1%[34] - The company reported a net investment income of ¥3,667,462.80, an increase from ¥3,437,976.21 in the previous period[37] - Other comprehensive income after tax for the current period was ¥8,898.18, compared to a loss of ¥25,527.99 in the previous period[38]